4 Post-Earnings Losers Drawing Unusual Options Volume

Hims & Hers Health (HIMS), GeneDx (WGS), Groupon (GRPN), and Digital Turbine (APPS) are down 19.3%, 16.8%, 25.1%, and 35.1% respectively, after earnings reports. HIMS reported a loss and lowered guidance. WGS beat estimates but lowered outlook. GRPN missed estimates. APPS beat estimates but had weak margins. Options volume is high, with bearish sentiment for most.

Original reporting
Published Nov 10, 2026, 6:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 6:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
4 Post-Earnings Losers Drawing Unusual Options Volume — source image
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The earnings misses and guidance cuts are fresh, driving significant price declines and heavy bearish options flow across the four stocks.

02

Market read

The article signals heightened short‑term risk for the four stocks and may prompt traders to consider bearish positions or options strategies.

03

What to watch

Potential short‑term technical rebounds could occur if options sellers unwind positions.

Relevance 7/10Novelty 7/10Timing: today, post‑earnings

Background

Post‑earnings options activity roundup focusing on four companies that posted losses or weak guidance, triggering large intraday moves.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Hims & Hers reported a surprise Q3 loss and cut revenue outlook, sending the stock down 19.3% with heavy bearish options volume.

Expected impact

likely further downside as market prices in the revenue outlook cut.

Evidence & confidence

The earnings miss and guidance cut are fresh facts; options delta is strongly negative, indicating traders expect more declines.

$WGSBearishHigh confidence
Context

GeneDx posted better‑than‑expected earnings but a weak Q4 outlook and a BTIG price‑target cut, causing a 16.8% drop and high bearish options activity.

Expected impact

downside pressure as investors digest the weaker guidance.

Evidence & confidence

Guidance and target cut are new, and options delta is negative, signaling continued selling.

$GRPNBearishHigh confidence
Context

Groupon missed Q3 earnings and revenue expectations, posting a larger loss than anticipated, leading to a 25.1% plunge and strong bearish options flow.

Expected impact

further decline likely as market reacts to the miss.

Evidence & confidence

Earnings miss is fresh; heavy bearish options volume confirms trader sentiment.

$APPSBearishHigh confidence
Context

Digital Turbine beat earnings but offered a flat EBITDA outlook and weaker margins, causing a 35.1% drop despite some contrarian bullish options activity.

Expected impact

downward pressure expected as outlook dominates the reaction.

Evidence & confidence

The flat outlook is new information; bearish price move outweighs the modest bullish options delta.

Market effects

Highlights heightened volatility in the telehealth, genomics, e‑commerce and mobile app sectors after earnings season.

U.S. equity markets may see broader pressure on small‑cap growth names.

Limited to U.S. listed companies; no direct global macro effect.

Counterpoint

APPS shows a modest bullish options delta, suggesting some traders see upside if the flat outlook is temporary.

Key entities

  • Hims & Hers Health Inc

    Telehealth provider reporting surprise loss and lowered outlook.

  • GeneDx Holdings Corp

    Genomics firm with earnings beat but weak outlook.

  • Groupon Inc

    Online marketplace missing earnings expectations.

  • Digital Turbine Inc

    Mobile app platform with flat outlook despite earnings beat.

Related articles

$HIMSMedAI 8/10

Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week

Hims & Hers (HIMS) shares fell 25.67% last week, despite a deal with Eli Lilly (LLY) announced on November 6. HIMS reported Q3 revenue of $890.37M, up 48.65%, but margins dropped to 57% from 74%. Lilly's Q3 revenue rose 38.61% to $24.397B, and it raised its full-year outlook to $91B-$92B. HIMS's subscriber base shrank by 100,000 to 2.8M, and it cut full-year Adjusted EBITDA guidance to $257M-$277M.

$HIMSHighAI 8/10

Hims & Hers earnings analysis: questions answered and next catalysts

Hims & Hers Health (HIMS) reported Q3 FY2026 revenue of $890.4M, up 49% YoY but slightly below estimates. Adjusted EPS was -$0.14, missing expectations. Management raised international revenue outlook and expects positive free cash flow for 2026-2027. The stock is down 19.53% as of Nov 10, 2026, following a 40% drop in the prior month. Key catalysts include the Peptides+ launch and Q4 earnings.

$HIMSHighAI 8/10

Hims & Hers Health Inc (HIMS) (Q3 2026) Earnings Call Highlights: Revenue Surges 49%

Hims & Hers Health Inc. (HIMS) reported Q3 2026 revenue growth of 49%, but subscribers declined by 100,000 to 2.8 million due to reduced marketing. Gross margins fell to 57%, and GAAP net loss was $33 million. Full-year adjusted EBITDA guidance was lowered to $257-$277 million. The company plans to increase marketing and expects subscriber growth to recover in Q1 2027. Management discussed strategic shifts, including peptide launches and international expansion.

$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.